Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Cell biology

Potential dementia treatment target identified using stem cell research

Researchers have identified a new treatment target for treating a common form of dementia after studying stem cells derived from patients.

Dementia treatment target identified using stem cell research

Source: Susanna Raitano/Stem Cell Reports 2014

Belgian researchers studied stem cells derived from patients with frontotemporal dementia (the green staining indicates the cortical marker CTIP2, the red stain is the neuronal marker TUJ1, and the blue stains the nuclei of the cells).

A stem cell model of a certain type of dementia has pointed to a new potential target for treatments, according to research published in Stem Cell Reports[1] on 31 December 2014. 

Stem cells with a mutation that causes frontotemporal dementia (FTD) are less able to develop into cortical neurons than stem cells without the mutation, it was found. Researchers used this model to identify processes inside the cell that are going wrong and that could be targeted by future treatments. 

FTD is the third leading cause of dementia in those aged under 65 years and yet there are no effective treatments for the condition, according to the Alzheimer’s Society.

This type of dementia has a strong genetic association — 40% of patients have a family history and their disease is usually linked to mutations in one of three genes.

Researchers at the Stem Cell Institute in Leuven, Belgium, took skin cells from patients with FTD who had mutations in a gene for progranulin, a protein that tells certain cells how to grow and develop.

Previous research into FTD using these types of stem cells looked at their ability to become a mixture of different types of neuron (brain cells). But this research looks specifically at the stem cells’ ability to become cortical neurons, the type of brain cell most affected in FTD. Development into cortical neurons decreased in the stem cells with the progranulin mutation and correcting the mutation — by inserting a healthy copy of the gene — reverses this effect.

Researchers also tried to identify how this mutation might be hindering cortical neuron development and they found that a signalling pathway called Wnt is very active compared to stem cells without the progranulin mutation. To confirm that the Wnt signalling pathway plays a role, the scientists inhibited Wnt and found that this allows the stem cells to develop into cortical neurons. The scientists now believe Wnt could be a therapeutic target in the future.

“Turning patient skin cells into brains cells in a dish holds tremendous promise for research into the condition as it allows us to unpick the complex biological pathways that go wrong in the brains of those affected,” says a spokeswoman for the Alzheimer’s Society. “As this research study shows, this can help researchers identify potential targets for the development of new drug treatments.”

The study’s authors believe the research supports the idea that the cellular and molecular defects in patients with this type of dementia may already be present in patients at a much younger age than when they develop the disease. “Causes of these diseases of aging may often already be present earlier in life and [this suggests] that additional events ultimately lead to the full manifestation of the symptoms of the disease,” say the authors.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067496

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.